Revolutionizing Healthcare with LucentAD

Unlock the power of LucentAD p-Tau 217 to impact the lives of your patients experiencing cognitive symptoms. This non-invasive, easy-to-use blood test is readily available to you via electronic ordering, convenient to use, and affordable for your patients. In just ten business days from receipt of sample, Lucent Diagnostics CLIA-certified laboratory will provide you with an easy-to-read report with high accuracy rule-in/rule-out data in most cases that could impact final diagnosis of Alzheimer’s Disease in your patients.

Alzheimer’s Pathology Detection Made Simple 

LucentAD p-Tau 217 is a revolutionary blood test that utilizes the ultra-sensitive capabilities of Quanterix proprietary Simoa® technology, to help identify amyloid pathology with high confidence in patients with cognitive impairment. The product identifies the presence of p-Tau 217, the only plasma biomarker identified by NIA-AA as appropriate for diagnosis of amyloid pathology for Alzheimer’s Disease. This product is a gamechanger. Accessible, convenient, and affordable, go beyond the limit of detection with LucentAD.

Join Us Today

Join us on this transformative journey. Discover how LucentAD, powered by Quanterix, can empower you with the knowledge and confidence to navigate the complexities of Alzheimer’s disease. Take control of your health and unlock a brighter future today.


The information provided on this website is for educational purposes only and should not be considered as medical advice. Please consult with your healthcare provider for personalized guidance and treatment options.